Current therapies for antibody-mediated autoimmune diseases largely rely on broad immunosuppression or lineage-wide B-cell depletion. These approaches are associated with increased risks of infection and other adverse effects. This commentary focuses on Chimeric Autoantibody Receptor (CAAR) T-cell technology as a precision immunotherapy that selectively eliminates pathogenic autoreactive B-cell clones while preserving protective immunity. Using Pemphigus Vulgaris (PV) as a representative model, CAAR-T cells engineered to express desmoglein 3 (Dsg3) demonstrate antigen-specific targeting of B cells expressing anti-Dsg3 B cell receptors. Notably, these cells maintain cytolytic efficacy despite high circulating autoantibody titers and show tissue selectivity, sparing keratinocytes, potentially due to biophysical constraints governing immune synapse formation. We further discuss key translational challenges, including manufacturing complexity, the presence of additional pathogenic antibody populations (e.g., anti-Dsg1), and long-term cellular persistence. Collectively, CAAR-T technology represents a mechanistically distinct and potentially scalable therapeutic paradigm for antibody-mediated autoimmune disorders, emphasizing antigenspecific immune editing over global immune suppression.

Pemphigus, Dsg3, CAAR T-cell therapy, Autoimmune diseases